“The ability to control the delivery of a drug to a targeted depth is a significant development. The ability to deliver a
drug to a designated depth can both increase the efficacy of a drug, as well as possibly enable a decrease in the
amount of ‘drug’ needed to achieve the required therapeutic or prophylactic outcome.
While the technology was primarily developed as part of the ‘Needle-free Injection’ project, the patent may have
wider applications.”
And from a previous announcement
“Finally, commercial negotiations are at an advanced stage in respect of the further development, deployment and distribution of the KarmelSonix product range, including the WIM-PC and other products currently under development. A further announcement in respect of these negotiations is expected in the near term.”
- Forums
- ASX - By Stock
- contract deal...will set it 40c
“The ability to control the delivery of a drug to a targeted...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries